The Evolving TKI Pipeline

Several agents are being investigated for durability and clinical potential in retinal vascular disease.

By: Simrat K. Sodhi, MSc, MB BChir (Cantab), David S. Boyer, MD

Retinal Physician March 1, 2026 Vol 23, Issue March-April 2026 Page(s): 13-15, 24

1

Anti-VEGF agents revolutionized treatment for retinal vascular diseases but impose significant burdens on healthcare systems and patients.
2

Tyrosine kinase inhibitors (TKIs) are being researched to enhance visual outcomes and decrease treatment frequency in conditions like nAMD and DME.
3

Vorolanib, a nonselective TKI, is combined with a bioerodible implant for sustained release, showing promising results in clinical trials.
4

Axitinib, delivered via an intravitreal implant, has shown comparable efficacy to aflibercept in trials for nAMD and DME.
5

D4517.2, a novel TKI, demonstrated significant reductions in treatment burden in a phase 2 study for nAMD and DME.

1